-+ 0.00%
-+ 0.00%
-+ 0.00%

Korro Bio doses first healthy-volunteer cohort in Phase 1/2 ANCHOR trial of KRRO-121

PUBT·10/05/2026 20:07:15
Listen to the news
Korro Bio doses first healthy-volunteer cohort in Phase 1/2 ANCHOR trial of KRRO-121
  • Korro Bio dosed the first healthy-volunteer cohort in its Phase 1/2 ANCHOR trial of KRRO-121 for hyperammonemia.
  • No clinical results have been presented; an interim readout is expected in the second half of 2027.
  • The program is designed to establish safety in healthy volunteers, then assess clinical activity in urea cycle disorder patients.
  • The first cohort received a single 2 mg/kg dose; patient dosing is expected to start in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Korro Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610051605PRIMZONEFULLFEED9839816) on October 05, 2026, and is solely responsible for the information contained therein.